Abstract: Provided herein are microneedle particles, compositions that include microneedle particles, methods of treating skin, and methods of delivering a substance of interest. The microneedle particles may include one or more microneedles, and the microneedle particles may be configured to prevent the entire microneedle particle from penetrating the biological tissue. The microneedle particles may be dispersed in a liquid medium to form a composition. A biological tissue may be contacted with the microneedle particles to pre-treat the biological tissue, and a substance of interest may be applied to the pre-treated biological tissue.
Abstract: Aqueous dispersions of chemically and physically stable particles for use in delivery of active pharmaceutical ingredients and processes for their production and use to enhance a biological response to an active pharmaceutical ingredient and prophylactically or therapeutically treat a subject are provided. Vaccines, wherein the active pharmaceutical ingredient is a solution of subunit vaccine antigen mixed with a colloidal dispersion of electrically charged particles and use of such vaccines in immunization are also provided.
Type:
Grant
Filed:
March 31, 2008
Date of Patent:
February 15, 2022
Assignee:
PARTICLE SCIENCES, INC.
Inventors:
Andrew Loxley, Mark Mitchnick, David Fairhurst, Christy Ann Eatmon
Abstract: The invention provides a method of inducing satiety in a subject comprising a step of orally administering a composition comprising an effective amount of a first agent capable of inducing satiety and of a second agent capable of augmenting the satiety-inducing effect of the first agent. Also disclosed are compositions for carrying out the method and a body weight management system comprising such compositions in combination with a device configured for the collection, storage and/or display of information relating to a subject's response to a predefined therapeutic regimen of orally administering the composition.
Abstract: The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having a coating made at least in part using printing technologies to provide drug storage and drug release structures. The coating preferably includes at least one drug reservoir layer and a least one barrier layer, and can include structures, such as but not limited to capillary structures that alone or in combination modulate the release of the drug from the coating. One aspect of the present invention is a medical device that incorporates a drug in at least one coating.
Abstract: A method of coating a peptide or protein useful for improving the cellular activity related to bone growth on an inorganic particle comprises the steps of freezing the residual liquid present on uncoated and or coated inorganic particles, and drying the uncoated or coated inorganic particles after freezing the residual liquid, the drying comprising causing the frozen residual liquid to sublime under vacuum. Further disclosed embodiments of the invention include further processes for forming inorganic particles coated with a peptide or protein useful for improving cellular activity related to bone growth and medical devices comprising the coated particles.
Type:
Grant
Filed:
February 21, 2019
Date of Patent:
February 1, 2022
Assignee:
Cerapedics, Inc.
Inventors:
Jevon Nyemscek, Jessica Stufflet, Nicolas Roscioli, Doug Millard, Katherine Suzanne Davis, Nolan Chase Hannigan, Tristan Stuart Barnes, Jerome Connor
Abstract: The present invention provides a method for preparing a bone protein preparation which contains for example growth factors. The present invention also provides a bone protein preparation obtained by the method and paste, putty, pellet, disc, block, granule, osteogenic device or pharmaceutical composition containing said bone protein preparation.
Type:
Grant
Filed:
May 5, 2020
Date of Patent:
January 11, 2022
Assignee:
BBS-Bioactive Bone Substitutes OYJ
Inventors:
Hanna Tölli, Juha-Matti Närhi, Harri Lumme, Elli Birr, Oili Hietala, Mikko Viitanen, Merja Haikola, Pekka Jalovaara, Bo Kenneth Sandström
Abstract: Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.
Type:
Grant
Filed:
September 6, 2019
Date of Patent:
December 28, 2021
Assignee:
Neurotech, USA, Inc.
Inventors:
Jeffrey Louis Goldberg, Cahil McGovern, Weng Tao, Konrad A. Kauper
Abstract: Implantable devices for orthopedic, including spine and other uses are formed of porous reinforced polymer scaffolds. Scaffolds include a thermoplastic polymer forming a porous matrix that has continuously interconnected pores. The porosity and the size of the pores within the scaffold are selectively formed during synthesis of the composite material, and the composite material includes a plurality of reinforcement particles integrally formed within and embedded in the matrix and exposed on the pore surfaces. The reinforcement particles provide one or more of reinforcement, bioactivity, or bioresorption.
Type:
Grant
Filed:
September 18, 2018
Date of Patent:
November 23, 2021
Assignee:
HAPPE SPINE LLC
Inventors:
Ryan K. Roeder, Gabriel L. Converse, Stephen M. Smith
Abstract: The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions.
Type:
Grant
Filed:
April 4, 2018
Date of Patent:
November 2, 2021
Assignee:
NOVALIQ GMBH
Inventors:
Bastian Theisinger, Sonja Theisinger, Bernhard Günther
Abstract: Disclosed are gel compositions suitable for the topical administration of an active compound having poor solubility and skin penetration, for example, of a COX-2 inhibitor compounds, processes of preparation thereof and methods of use thereof for the treatment of indications treatable by the active compound.
Type:
Grant
Filed:
September 13, 2013
Date of Patent:
October 26, 2021
Assignee:
EGIS Pharmaceuticals PLC
Inventors:
Endre Mikulásik, Tamás Spaits, Ágota Szakálynè Sinka
Abstract: A method for treating pulmonary arterial hypertension in a patient can include determining whether a patient with pulmonary arterial hypertension has an enlarged right ventricle or right ventricular dysfunction, where the patient has previously been administered a prostanoid and weaning the patient off of the prostanoid if the patient does not have an enlarged right ventricle or right ventricular dysfunction.
Type:
Grant
Filed:
January 7, 2013
Date of Patent:
October 26, 2021
Assignee:
VERO Biotech LLC
Inventors:
Tammy Watts, Robert F. Roscigno, David H. Fine, Lewis J. Rubin
Abstract: Bioactive porous bone graft implants in various forms suitable for bone tissue regeneration and/or repair, as well as methods of use, are provided. The implants are formed of bioactive glass and have an engineered porosity. The implants may take the form of a putty, foam, fibrous cluster, fibrous matrix, granular matrix, or combinations thereof and allow for enhanced clinical results as well as ease of handling.
Type:
Grant
Filed:
July 1, 2019
Date of Patent:
September 28, 2021
Assignee:
PROSIDYAN, INC.
Inventors:
Charanpreet S. Bagga, Steve B. Jung, Hyun W. Bae
Abstract: A medical composition and devices made from the composition for the delivery of extracts obtained from Boswellia genus, similar compounds synthetically derived, and in particular derivatives of triterpenes is disclosed. The medical device may be implantable, or alternatively a device which contacts the interior of a mammalian body. The medical device may be comprised, of or present an absorbable component containing Boswellia derivatives, or an eluting component. When administered into a particular body site, the Boswellia component may be released substantially and immediately, released slowly, or not released, into the body and residing actively on the medical device surface.
Type:
Grant
Filed:
June 21, 2012
Date of Patent:
September 21, 2021
Assignee:
BVW Holding AG
Inventors:
Michael T. Milbocker, Lukas von Bluecher
Abstract: A platinum(II) complex loaded on a mesosilicalite nanocarrier having a hierarchical silicalite characterized by a molar ratio of aluminum to silica in a range of 1:3000 to 1:1000. The hierarchical silicalite includes mesopores of a hexagonal structure, and micropores of silicalite structure with a microporous volume in the range of 0.05 cc/g to 0.1 cc/g. The mesosiliclite nanocarrier loaded with the platinum(II) complex is suitable for treatment of cancer, in particular, breast, cervical, and colon cancers.
Abstract: The invention relates to an oral tablet suitable for active pharmaceutical ingredients comprising a population of particles, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting in induced saliva generation upon mastication of the tablet.
Abstract: The invention relates to a tablet dosage form for buccal absorption of active ingredients comprising a population of particles and an active ingredient to be released in the oral cavity for absorption through the oral mucosa, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas.
Abstract: A mesosilicalite nanocarrier having a hierarchical silicalite characterized by a molar ratio of aluminum to silica in a range of 1:3000 to 1:1000. The hierarchical silicalite includes mesopores of a hexagonal structure, and micropores of silicalite structure with a microporous volume in the range of 0.05 cc/g to 0.1 cc/g. The nanocarrier has a mesophase content in the range of 30 wt % to 70 wt %, a microphase content in the range of 30 wt % to 70 wt %, and a mean pore diameter in the range of 1.5 nm to 5.5 nm. A method of preparing the stable mesosilicalite nanocarrier with hierarchical micro/mesopores to load an antioxidant or drug for targeted drug delivery is also described.
Abstract: The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having a coating made at least in part using printing technologies to provide drug storage and drug release structures. The coating preferably includes at least one drug reservoir layer and a least one barrier layer, and can include structures, such as but not limited to capillary structures that alone or in combination modulate the release of the drug from the coating. One aspect of the present invention is a medical device that incorporates a drug in at least one coating.
Abstract: The invention provides an improved lipid-based nanoparticle, which can be used to deliver a therapeutic agent to a subject, such as but not limited to a mammal, such as but not limited to a human. In certain embodiments, the nanoparticle of the invention has reduced aggregation properties as compared to those taught in the prior art.
Abstract: The invention relates to a disintegrating oral tablet suitable for active pharmaceutical ingredients comprising a population of particles and at least one flavor ingredient, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting in a burst of the at least one flavor ingredient upon mastication of the tablet.